Biodexa Pharmaceuticals PLC (BDRX)
5.68
-0.23
(-3.89%)
USD |
NASDAQ |
Nov 04, 16:00
5.68
0.00 (0.00%)
After-Hours: 20:00
Biodexa Pharmaceuticals Enterprise Value: -2.612M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | -2.612M |
| November 01, 2024 | -2.478M |
| October 31, 2024 | -2.338M |
| October 30, 2024 | -2.310M |
| October 29, 2024 | -2.042M |
| October 28, 2024 | -2.129M |
| October 25, 2024 | -2.246M |
| October 24, 2024 | -2.068M |
| October 23, 2024 | -1.804M |
| October 22, 2024 | -2.286M |
| October 21, 2024 | -2.437M |
| October 18, 2024 | -2.600M |
| October 17, 2024 | -2.501M |
| October 16, 2024 | -1.032M |
| October 15, 2024 | -3.001M |
| October 14, 2024 | -2.873M |
| October 11, 2024 | -2.861M |
| October 10, 2024 | -3.036M |
| October 09, 2024 | -3.128M |
| October 08, 2024 | -2.646M |
| October 07, 2024 | -2.449M |
| October 04, 2024 | -2.687M |
| October 03, 2024 | -2.421M |
| October 02, 2024 | -1.859M |
| October 01, 2024 | -1.467M |
| Date | Value |
|---|---|
| September 30, 2024 | -1.813M |
| September 27, 2024 | -1.734M |
| September 26, 2024 | -1.627M |
| September 25, 2024 | -1.676M |
| September 24, 2024 | -1.660M |
| September 23, 2024 | -1.935M |
| September 20, 2024 | -1.669M |
| September 19, 2024 | -0.5961M |
| September 18, 2024 | -0.5003M |
| September 17, 2024 | -0.3783M |
| September 16, 2024 | -0.101M |
| September 13, 2024 | 0.0718M |
| September 12, 2024 | -0.2476M |
| September 11, 2024 | 0.188M |
| September 10, 2024 | 0.3738M |
| September 09, 2024 | -0.0153M |
| September 06, 2024 | -0.6455M |
| September 05, 2024 | -0.1605M |
| September 04, 2024 | 0.4784M |
| September 03, 2024 | 0.6976M |
| August 30, 2024 | 2.076M |
| August 29, 2024 | 2.119M |
| August 28, 2024 | 2.470M |
| August 27, 2024 | 2.656M |
| August 26, 2024 | 3.165M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-5.110M
Minimum
Dec 28 2022
35.46M
Maximum
Feb 04 2021
6.904M
Average
3.105M
Median
Jun 09 2020
Enterprise Value Benchmarks
| Adaptimmune Therapeutics PLC | 18.55M |
| Verona Pharma PLC | 2.817B |
| NuCana PLC | -11.24M |
| Autolus Therapeutics PLC | 182.82M |
| TC BioPharm (Holdings) PLC | -0.5511M |
Enterprise Value Related Metrics
| Earnings Yield | -1.31K% |
| Normalized Earnings Yield | -4770.80 |